Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yuki Okuhiro"'
Autor:
Kazuki Tanimura, Kai Yamasaki, Yuki Okuhiro, Kota Hira, Chika Nitani, Keiko Okada, Hiroyuki Fujisaki, Kana Matsumoto, Junichi Hara
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 24-28 (2021)
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) reported to show a higher efficacy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) than other TKIs. However, few studies describe ponatinib for pediatric
Externí odkaz:
https://doaj.org/article/2831b36850924622a7819ce0abc83cf9
Autor:
Chika Nitani, Junichi Hara, Kai Yamasaki, Kazuki Tanimura, Hiroyuki Fujisaki, Keiko Okada, Kana Matsumoto, Kota Hira, Yuki Okuhiro
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 14, Iss 1, Pp 24-28 (2021)
Case Reports in Oncology, Vol 14, Iss 1, Pp 24-28 (2021)
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) reported to show a higher efficacy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) than other TKIs. However, few studies describe ponatinib for pediatric
Autor:
Yuki Okuhiro, Noritsugu Kunihiro, Hiroko Fukushima, Kosei Nakajima, Makoto Miyazaki, Rei Noguchi, Kai Yamasaki, Rieko Oyama, Mutsumi Takadera, Takeshi Inoue, Tatsuya Ozawa, Tadashi Kondo, Junichi Hara, Yui Kimura, Zhiwei Qiao, Koichi Ichimura, Yoshiko Nakano
Publikováno v:
Human Cell. 34:271-278
Atypical teratoid/rhabdoid tumor (AT/RT) is a rare intracranial tumor occurring predominantly in young children. The prognosis is poor, and no effective treatment is currently available. To develop novel effective therapies, there is a need for exper
Autor:
Junichi Hara, Chiaki Murakami, Hiroko Fukushima, Mai Honda-Kitahara, Koichi Ichimura, Takashi Kohno, Kai Yamasaki, Yuki Okuhiro, Yoshiko Nakano, Noritsugu Kunihiro, Sumihito Nobusawa, Tatsuya Ozawa, Takeshi Inoue, Kouya Shiraishi, Junko Hirato, Yasuhiro Matsusaka
Publikováno v:
Neuropathology and Applied Neurobiology. 46:190-193
Autor:
Kohei, Matsubara, Kai, Yamasaki, Kazuki, Tanimura, Kota, Hira, Yuki, Okuhiro, Yuko, Ishii, Chika, Nitani, Keiko, Okada, Hiroyuki, Fujisaki, Junichi, Hara
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 48(4)
Gemcitabine and Docetaxel(GEM/DTX)are well known chemotherapeutic drugs for the treatment of soft tissue sarcomas. However, the efficacy of these drugs in the treatment of malignant rhabdoid tumors(MRTs)has not been well described. We used GEM/DTX as
Autor:
Hiroko Fukushima, Keiko Okada, Koichi Ichimura, Hiroaki Sakamoto, Junichi Hara, Yuki Okuhiro, Kaishi Satomi, Yoshiko Nakano, Yuko Osugi, Takeshi Inoue, Akihiko Yoshida, Kai Yamasaki
Publikováno v:
Pediatric Blood & Cancer. 67
Autor:
Yoshiko, Nakano, Mutsumi, Takadera, Makoto, Miyazaki, Zhiwei, Qiao, Kosei, Nakajima, Rei, Noguchi, Rieko, Oyama, Yui, Kimura, Yuki, Okuhiro, Kai, Yamasaki, Noritsugu, Kunihiro, Hiroko, Fukushima, Takeshi, Inoue, Junichi, Hara, Tatsuya, Ozawa, Tadashi, Kondo, Koichi, Ichimura
Publikováno v:
Human cell. 34(1)
Atypical teratoid/rhabdoid tumor (AT/RT) is a rare intracranial tumor occurring predominantly in young children. The prognosis is poor, and no effective treatment is currently available. To develop novel effective therapies, there is a need for exper
Autor:
Junichi Hara, Hiroaki Sakamoto, Noritsugu Kunihiro, Kota Hira, Yuki Okuhiro, Hiroyuki Fujisaki, Kazuki Tanimura, Yasuhiro Matsusaka, Kai Yamasaki, Chika Nitani, Keiko Okada
Publikováno v:
Neuro-Oncology
BACKGROUND The prognosis of relapsed medulloblastoma was dismal. Recently, we published the promising outcome of metastatic medulloblastomas treated with a double-conditioning regimen comprising high-dose thiotepa and melphalan (HD-TM). Here, we repo